Li Mingwu, Li Kai, Qi Xingshun, Wu Wenbin, Zheng Luanluan, He Chuangye, Yin Zhanxin, Fan Daiming, Zhang Zhuoli, Han Guohong
Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, 127 West Chang le Road, Xi'an 710032, China.
State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, 127 West Chang le Road, Xi'an 710032, China.
J Vasc Interv Radiol. 2016 Jul;27(7):1047-1055.e2. doi: 10.1016/j.jvir.2016.02.035. Epub 2016 May 27.
To evaluate prognostic factors for stent patency and survival in patients with perihilar cholangiocarcinoma (pCCA) who underwent percutaneous biliary stent placement.
This prospective study followed 92 consecutive patients with pCCA who underwent metal stent placement between January 2013 and July 2014. Of the total number of patients, 11 had ascites, and 36 had biliary obstruction for > 1 month at the time of stent placement. Cumulative patency and survival rates were assessed with Kaplan-Meier curves, and independent predictors were calculated with Cox regression. A new formula was developed to predict patient survival.
Tumor size was significantly associated with stent patency (hazard ratio = 2.425; 95% confidence interval, 1.134-5.168). Independent predictors of survival included lymph node metastasis, intrahepatic mass lesion, cancer antigen 19-9 (CA19-9), ascites, and duration of jaundice. A new equation was developed to assess risk: R = 7 × (duration of biliary obstruction-0 if < 30 d, 1 if > 30 d) + 7 × (CA19-9-0 if < 500, 1 if > 500) + 7 × (ascites-0 if none present, 1 if ascites present) + 10 × (lymph node metastasis-0 if no metastasis, 1 if metastasis present) + 9 (intrahepatic mass lesion-0 if absent, 1 if present). Among patients who developed stent occlusion, patients who underwent recanalization of the occluded stent had longer survival compared with patients who did not undergo recanalization (109 d vs 29 d, P = .001).
Prognostic factors for survival after percutaneous stent placement in patients with pCCA were tumor stage, duration of jaundice, CA19-9, and ascites. Tumor size affected stent patency. Prognosis for patients with reintervention after occlusion of the stent improved.
评估接受经皮胆道支架置入术的肝门部胆管癌(pCCA)患者支架通畅性及生存情况的预后因素。
这项前瞻性研究纳入了2013年1月至2014年7月期间连续92例行金属支架置入术的pCCA患者。患者总数中,11例有腹水,36例在支架置入时胆道梗阻超过1个月。采用Kaplan-Meier曲线评估累积通畅率和生存率,并用Cox回归计算独立预测因素。开发了一个新公式来预测患者生存情况。
肿瘤大小与支架通畅性显著相关(风险比=2.425;95%置信区间,1.134 - 5.168)。生存的独立预测因素包括淋巴结转移、肝内肿块病变、癌抗原19-9(CA19-9)、腹水和黄疸持续时间。开发了一个新方程来评估风险:R = 7×(胆道梗阻持续时间 - 若<30天为0,若>30天为1)+ 7×(CA19-9 - 若<500为0,若>500为1)+ 7×(腹水 - 若无腹水为0,若有腹水为1)+ 10×(淋巴结转移 - 若无转移为0,若有转移为1)+ 9(肝内肿块病变 - 若无病变为0,若有病变为1)。在发生支架闭塞的患者中,接受闭塞支架再通的患者比未接受再通的患者生存时间更长(109天对29天,P = 0.001)。
pCCA患者经皮支架置入术后生存的预后因素为肿瘤分期、黄疸持续时间、CA19-9和腹水。肿瘤大小影响支架通畅性。支架闭塞后接受再次干预的患者预后改善。